Early and accurate detection of prostate cancer is an urgent priority because it is the most prevalent type of cancer in men and the second most frequent cause of cancer deaths in men. New prostate cancer cases in the United States for 2004 were estimated at 23,110, and deaths were estimated at 29,900 (1). Current screening of serum prostate-specific antigen (PSA) levels and with digital rectal examination (DRE) followed by ultrasonographically (US)-guided prostate biopsy have some substantial shortcomings. Transrectal US depicts only 64% of cancers per gland (2, 3), and 32%–42% of cancers per lobe (3, 4). With random biopsy, up to 32% of cancers are missed when comparing biopsy results per lobe with prostatectomy specimens (3). These invisible cancers are as important as those visible at transrectal US (5). In PSA-screened populations, the per patient accuracy of transrectal US was only 52% owing to the large number of false-positive findings encountered (6). In this same group, DRE, which helps
Radiology

Support for this study, in the form of a loaned B-scan imaging system (Logiq-7), was received from GE Medical Systems, Milwaukee, Wis. The authors had control of all data and information submitted for publication.

Sonoelastographic images are vibration amplitude images in which stiff regions (those with a high elastic modulus) appear as areas of low vibration relative to the surrounding softer tissue, which transmits vibration more readily. Color Doppler US is used to display the vibration differences, with high vibration displayed as bright green and low vibration as dark green. The Doppler image is overlaid on the gray-scale image, which permits simultaneous coregistered image acquisition. A stiff lesion causes a local decrease in the vibration field, which is displayed as a void or dark region on the color Doppler image.

Gland Selection and Reference Standard

Excised glands were selected from patients with prostate cancer who (a) were scheduled to undergo radical prostatectomy (so that 3D histologic slices could be obtained as the reference standard), (b) had a palpable lesion at DRE or at least one core specimen that was 50% positive for tumor at preoperative biopsy, and (c) did not undergo hormonal or radiation therapy. The patients ranged in age from 46 to 70 years, with an average age of 60.5 years. This study was approved by our institutional review board and was compliant with the Health Insurance Portability and Accountability Act. Informed consent was obtained for the use of the excised gland. Nineteen glands were selected from November 2001 through August 2003.

The selection criteria did not include patients with prostate cancer in whom the tumor volume was estimated to be less than approximately 1 cm³ and others in whom the entire prostate and tumor had been treated with radiation or hormonal therapy, which alters the gland stiffness and the amount of residual tumor. Also eliminated from the study were those rare patients with a tumor so advanced as to leave questionable “normal” regions.

Scanning

The details of the scanning protocol and the blinded reading protocol were as follows: Specimens were obtained immediately after surgical excision, embedded in 3.4% agar gel, and imaged with a 3D protocol. Coregistered sonoelastographic and B-mode US images were obtained at 1-mm spacing by using a linear 7-MHz probe (model 739L; GE Medical Systems) mounted on a motorized track (Velmax, Bloomfield, NY). Images were obtained by two authors (L.S.T. and Z.W.) with 2 years of experience in sonoelastographic imaging. Vibration was performed from a source opposite the probe, with frequencies of 100–300 Hz. A combination of frequencies (chords) was used to diminish artifacts. The highest frequency that adequately penetrated the tissue to give a uniform vibration field was chosen.

Pathologic Evaluation

After US, the fresh prostate gland was weighed and measured to determine the maximum dimension in all three planes from apex to base, transversely, and anteroposteriorly. The resection margins of the gland were inked with different colors that represented each quadrant. A landmark device, which consisted of two sets of four 3-mm-diameter mating metal prongs, was inserted into the specimen through the apex and base to provide fiducial markers. After fixation, the gland was remeasured to assess shrinkage, sliced into 4-mm-thick sections from the apex to the base, and digitally photographed. After being photographed, the tissues from the Petri dishes were transferred to cassettes and embedded in paraffin (Paraplast; Sherwood Medical, St Louis, Mo) to make blocks that were sliced into 4–5-μm-thick sections and placed on glass slides.

The microscopic whole-mount sections were examined by one of three pathologists (P.A.D.S., G.N., and P.N., all with more than 5 years of experience in pathology). The pathologists were blinded to the results at sonoelastography. Areas of carcinoma and benign nodular hyperplasia were outlined with two different color-marking pens, and the slides were submitted for 3D volume reconstruction. Digital photographs of each gross prostate slice and its accompanying histologic slide were processed with a computer program (Photoshop, version 5.5; Adobe, San Jose, Calif) by aligning each planar image with the puncture holes from the landmark device to generate the 3D reconstructions.

Reference Standard

Transverse 1-mm B-mode US scans were used to create a 3D image of the surface of the prostate. In each two-dimensional section, the boundary of the gland was outlined by B.C.P. and Z.W. to differentiate the gland from the background. The sequence of boundary outlines was reconstructed in three dimensions and used as the reference standard.

MATERIALS AND METHODS

Support for this study, in the form of a loaned B-scan imaging system (Logiq-7), was received from GE Medical Systems, Milwaukee, Wis. The authors had control of all data and information submitted for publication.

Sonoelastographic images are vibration amplitude images in which stiff regions (those with a high elastic modulus) appear as areas of low vibration relative to the surrounding softer tissue, which transmits vibration more readily. Color Doppler US is used to display the vibration differences, with high vibration displayed as bright green and low vibration as dark green. The Doppler image is overlaid on the gray-scale image, which permits simultaneous coregistered image acquisition. A stiff lesion causes a local decrease in the vibration field, which is displayed as a void or dark region on the color Doppler image.

Gland Selection and Reference Standard

Excised glands were selected from patients with prostate cancer who (a) were scheduled to undergo radical prostatectomy (so that 3D histologic slices could be obtained as the reference standard), (b) had a palpable lesion at DRE or at least one core specimen that was 50% positive for tumor at preoperative biopsy, and (c) did not undergo hormonal or radiation therapy. The patients ranged in age from 46 to 70 years, with an average age of 60.5 years. This study was approved by our institutional review board and was compliant with the Health Insurance Portability and Accountability Act. Informed consent was obtained for the use of the excised gland. Nineteen glands were selected from November 2001 through August 2003.

The selection criteria did not include patients with prostate cancer in whom the tumor volume was estimated to be less than approximately 1 cm³ and others in whom the entire prostate and tumor had been treated with radiation or hormonal therapy, which alters the gland stiffness and the amount of residual tumor. Also eliminated from the study were those rare patients with a tumor so advanced as to leave questionable “normal” regions.

Scanning

The details of the scanning protocol and the blinded reading protocol were as follows: Specimens were obtained immediately after surgical excision, embedded in 3.4% agar gel, and imaged with a 3D protocol. Coregistered sonoelastographic and B-mode US images were obtained at 1-mm spacing by using a linear 7-MHz probe (model 739L; GE Medical Systems) mounted on a motorized track (Velmax, Bloomfield, NY). Images were obtained by two authors (L.S.T. and Z.W.) with 2 years of experience in sonoelastographic imaging. Vibration was performed from a source opposite the probe, with frequencies of 100–300 Hz. A combination of frequencies (chords) was used to diminish artifacts. The highest frequency that adequately penetrated the tissue to give a uniform vibration field was chosen.

Pathologic Evaluation

After US, the fresh prostate gland was weighed and measured to determine the maximum dimension in all three planes from apex to base, transversely, and anteroposteriorly. The resection margins of the gland were inked with different colors that represented each quadrant. A landmark device, which consisted of two sets of four 3-mm-diameter mating metal prongs, was inserted into the specimen through the apex and base to provide fiducial markers. After fixation, the gland was remeasured to assess shrinkage, sliced into 4-mm-thick sections from the apex to the base, and digitally photographed. After being photographed, the tissues from the Petri dishes were transferred to cassettes and embedded in paraffin (Paraplast; Sherwood Medical, St Louis, Mo) to make blocks that were sliced into 4–5-μm-thick sections and placed on glass slides.

The microscopic whole-mount sections were examined by one of three pathologists (P.A.D.S., G.N., and P.N., all with more than 5 years of experience in pathology). The pathologists were blinded to the results at sonoelastography. Areas of carcinoma and benign nodular hyperplasia were outlined with two different color-marking pens, and the slides were submitted for 3D volume reconstruction. Digital photographs of each gross prostate slice and its accompanying histologic slide were processed with a computer program (Photoshop, version 5.5; Adobe, San Jose, Calif) by aligning each planar image with the puncture holes from the landmark device to generate the 3D reconstructions.

Reference Standard

Transverse 1-mm B-mode US scans were used to create a 3D image of the surface of the prostate. In each two-dimensional section, the boundary of the gland was outlined by B.C.P. and Z.W. to differentiate the gland from the background. The sequence of boundary outlines was reconstructed in three dimensions and used as the reference standard.
Pathology reports and sections were reviewed by three authors (P.A.d.S., G.N., or P.N.), who were blinded to the findings at US or sonoelastography, for tumor presence, size, and location. Locations, volumes, and types of adenomatous nodules (stromal or glandular) were recorded.

Sonoelastographic images were considered positive for tumor when a contiguous localized 3D vibration deficit was present for more than 2 mm in the craniocaudal direction. Sonoelastographic imaging defects could be focal (well circumscribed with no vibration) or diffuse (poorly circumscribed with green pixels [vibration] incompletely filling in the grayscale image). B-mode US scans were considered positive for tumor when a discrete 3D hypoechoic nodule or region was identified or if there was a local mass of any echogenicity disrupting the gland contour.

Three-dimensional coregistered pathologic, B-mode US, and sonoelastographic images were displayed as a 3D volume fusion with pathologic lesions in red, sonoelastic lesions in green, and overlap between pathologic and sonoelastographic lesions in bright yellow. In addition, sequential transverse two-dimensional images were examined. Pathologic and sonoelastographic lesion volumes, locations, and overlap measures were also recorded.

**Statistical Analysis**

The following definitions were used to record results within the 3D coregistered volumes: A true-positive finding was recorded for a local region of the prostate volume when a discrete lesion of pathologically confirmed cancer had substantial (approximately 50% or more) coregistration with a discrete lesion seen at sonoelastography or B-mode US. A false-positive finding was recorded for a local region of the prostate volume when a discrete lesion seen at sonoelastography or B-mode US had less than 50% coregistration with a pathologically confirmed cancer. A false-negative finding was recorded when a discrete cancer had no corresponding lesion at sonoelastography or B-mode US. A true-negative finding was recorded only if there was no cancer at pathologic examination and no lesion at sonoelastography or B-mode US.

In the data analysis, the total number of identified lesions was defined as the number of true-positive, true-negative, false-positive, and false-negative lesions; accuracy was determined by dividing the number of true-positive and true-negative findings by the total number of lesions; sensitivity was determined by di-
viding the number of true-positive findings by the number of true-positive and false-negative findings; and positive predictive value was calculated by dividing the number of true-positive findings by the number of true- and false-positive findings.

RESULTS

An example of a sonoelastographic void is shown in Figure 1. This approach is also applicable to in vivo clinical examination, as shown in Figure 2. The coregistration of B-mode surface, sonoelastography lesions, and pathology lesions in three dimensions is shown in Figure 3. A breakdown of the 3D coregistration into a sequence of stacked two-dimensional sections (1-mm thickness) is shown in Figure 4.

The results for both lesion groups are shown in Table 1. The average tumor volume (± standard deviation) for G1 lesions as determined at histologic examination was 3.0 cm³ ± 2.1. The average G1 tumor volume at sonoelastography, with use of only the five true-positive findings, was 2.8 cm³ ± 1.8. The average volume of the five histologic lesions to which they corresponded was 3.7 cm³ ± 2.2. The mean volume of the sonoelastographic tumors in this group was 93% of the mean histologically confirmed tumor volume. The mean size of the 22 histologically confirmed G2 lesions was 0.32 cm³ ± 0.21.

The ratio of intersection to union of whole-gland volumes ranged from 0.69 to 0.82 (20,21). A complete description of the 3D image registration protocol has been published elsewhere (21).

Within the 19 prostates evaluated were 29 discrete foci of cancer. These cancers ranged in volume from a maximum of 6.6 cm³ to less than 0.1 cm³. One prostate was found to have no pathologically confirmed cancer (within the limits of our 3-mm sampling of pathology slices); in addition, no lesions were seen at sonoelastography. This case was the only true-negative finding in the study.

By using sonoelastography, seven G1 lesions (pathologically confirmed focal lesions with a tumor volume of at least 1 cm³) were scored as five true-positive and two false-positive findings. In two cases, the lesion seen at sonoelastography did not match the pathologic tumor; these lesions were considered false-negative findings. Thus, the sensitivity was 71%, the accuracy was 55%, and the positive predictive value was 71%. Similarly, gray-scale (B-mode) US of the G1 lesions yielded two true-positive, five false-positive, and five false-negative findings; there were no true-negative findings. From this small sample, we find that the accuracy was 17% (two of 12 lesions), sensitivity was 29% (two of seven lesions), and positive predictive value was 29% (two of seven lesions). The results are shown in Table 2.

At sonoelastography of G2 lesions (22 pathologically confirmed tumors with volumes of less than 1 cm³), there were nine true-positive findings, 13 false-negative findings, six false-positive findings, and one true-negative finding. Thus, the sensitivity was 41%, the accuracy was 34%, and the positive predictive value was 60%.

DISCUSSION

The results of this study demonstrate that, in the examination of a whole gland for cancer, the sensitivity and accuracy with sonoelastography could be increased to levels of 71% and 55%, respectively, which are major improvements over the levels reported with conventional B-mode US. These results, however, are for a relatively small group of whole prostatectomy specimens (n = 7) with a focal tumor with a volume of more than 1.0 cm³.

The accuracy and sensitivity of sonoelastography were much poorer, however, for cases in which the individual cancers were smaller than 1.0 cm³. Results of our previous work have shown that the contrast on sonoelastographic images of lesions diminishes with decreasing frequency (23,24). Many G2 tumors are too small to generate sonoelastographic contrast at the frequencies we are currently using. In addition, as the size of the cancer approaches 0.1 cm³, we lack an understanding of the mechanical and elastic properties of the tumor and whether there is sufficient mechanical contrast in comparison with surrounding tissues to make a detectable void on a sonoelastographic image. It is possible that the stiffness of very small tumors may not be the same as that of larger tumors; the stiffness could be considerably less, especially compared with that of background tissue. Additional research into the biomechanical properties of prostate cancer is needed to provide the baseline data about this fundamental issue.

For G1 lesions, B-mode US values for prostate cancer detection are lower than those in other published studies (2–4);
Radiology

this may be due to our stricter requirement of substantial 3D coregistration to qualify as a true-positive finding. Comparison of in vitro transverse scanning versus real-time biplanar transrectal US introduces another issue in that longer real-time imaging and imaging in more than one plane may improve lesion detection.

Another factor in the poor accuracy and sensitivity in both groups was the prevalence of false-positive findings. Further analysis of the 3D images demonstrates that some of the false-positive voids seen on sonoelastographic images are owing to calculations or to regions of benign prostate hyperplasia, as confirmed at histologic examination. It is reasonable to hypothesize that calcified regions will manifest as "hard" sonoelastographic voids because these are easily visualized on the B-mode scan; these voids are straightforward to eliminate in practice. Not much is known, however, about the elastic properties of benign prostate hyperplasia—either the stromal or the glandular types. More information about this is needed because the grayscale US appearance of a benign prostate hyperplasia nodule also overlaps with that of cancer. Additional difficulties may be encountered in translating the results of this in vitro study to in vivo conditions, where patient motion and access constraints are present.

Finally, the comparison of volumes (3D sonoelastographic vs pathologic) is imprecise because of the coarse sampling of the whole specimens into 4-mm pathology specimens, compared with the 1-mm US scan acquisition. In addition, factors including tissue shrinkage and warping during preparation and the need for manual outlining of the pathologic slides contribute to the imprecise volume estimates from pathologic examination.

In conclusion, 3D sonoelastographic imaging of prostate cancer currently shows promise for the in vitro evaluation of lesions larger than 1 cm³ and an improvement over grayscale US. False-positive findings occur with calcifications (and can potentially be corrected by referencing the grayscale US scan) and adenomatous nodules, which currently cannot be differentiated from cancer with grayscale US or sonoelastography. The number of false-negative findings increases as the tumor size decreases, and this may be due to the underestimation of tumor size with sonoelastography and the limited image contrast resolution at the frequencies applied. Future work will require better understanding of the mechanical properties of tissue, the stiffness differential between tumor and normal tissue needed to provide image contrast, and the development of alternative vibration techniques to generate higher frequency shear waves at depth.

References